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BY-NC-ND license (http://creativecomAbstract This study aimed to determine the effect of surgical margin positivity on biochem-
ical recurrence (BCR) in patients with locally advanced prostate cancer (PCa) who underwent
radical retropubic prostatectomy (RRP). The medical records of all patients with locally
advanced PCa that underwent RRP were retrospectively reviewed. Patient demographics, dig-
ital rectal examination findings, prostate biopsy Gleason score, prostate volume, pre- and
post-treatment prostate-specific antigen (PSA) levels, definitive pathology Gleason score, sur-
gical margin status, seminal vesicle invasion, perineural invasion, absence or presence of BCR,
and the time to BCR were analyzed. The study included 130 patients. The final pathologic ex-
amination showed that seven (5.4%) patients had T3a disease and 123 (94.6%) had T3b disease.
In all, 93 (71.5%) patients had a positive surgical margin [SM(þ)], whereas 37 (28.5%) patients
had a negative surgical margin [SM()]. Among the seven patients with pT3a disease, four
(57.1%) had SM(þ), whereas 89 (72.4%) of the 123 patients with pT3b disease had SM().
BCR occurred in 11.8% (11 of 93) of patients with SM(þ) and in 45.9% (17 of 37) of those with
SM() (p < 0.001). Multivariate logistic regression analysis showed that SM(þ) was the only
significant predictor of BCR following RRP (relative risk, 0.163; 95% confidence interval
(0.062e0.433); p < 0.001). SM(þ) in RRP specimens is not always indicative of BCR in patients
with locally advanced PCa. RRP should be considered an effective treatment choice for
selected patients with locally advanced PCa, despite the associated high SM(þ) rate.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Prostate cancer (PCa) is the most common solid neoplasm in
males in Europe, with an incidence of 214 cases per 1000
males [1]. Both genetic and epigenetic factors play a role in
the etiopathogenesis and progression of PCa [1,2]. Radical
prostatectomy (RP) is the most common treatment in pa-
tients with localized PCa and a life expectancy >10 years.
Despite the favorable rate of cancer control associated
with RP, approximately 25% of all patients [3] and 60% of
patients with locally advanced PCa that undergo RP expe-
rience biochemical recurrence (BCR) within 10 years of
treatment [4].
The prostate biopsy Gleason score (GS) and pretreat-
ment serum prostate-specific antigen (PSA) level are well-
known predictors of BCR following RP [5,6]. Surgical margin
positivity (SMþ), which occurs in 38% of patients who
undergo RP, is also thought to be associated with BCR [6].
The present study aimed to determine the effect of SMþ on
BCR in patients with locally advanced PCa that underwent
radical retropubic prostatectomy (RRP).Table 1 Patient characteristics according to SM status.
SM() SM(þ) p
No. of patients
(n Z 130)
37 (28.5%) 93 (71.5%)
Age  SD (y) 64.86  5.55 64.08  6.23 0.5
PSA (ng/mL) 9.56  7.56 8.41  5.51 0.15
Biopsy GS 6.33  0.81 6.28  0.82 0.7
Final pathology GS 6.99  0.9 6.33  0.85 0.001
Prostate volume 38.27  15.99 39.52  14.49 0.66Material and methods
The medical records of all patients with pathologically
locally advanced PCa who underwent RRP between October
1, 2005 and October 1, 2015 were retrospectively reviewed.
Patients with a history of neoadjuvant or adjuvant therapy
for PCa were excluded from the study. The same RRP
technique was performed by multiple surgeons. Extended
lymph node dissection was performed in patients consid-
ered high-risk, according to D’Amico’s risk classification [7].
Patient demographics, digital rectal examination (DRE)
findings, prostate biopsy GS, prostate volume, pre- and
post-treatment PSA levels, free/total PSA ratio, definitive
pathology GS, surgical margin status, seminal vesicle inva-
sion, perineural invasion, presence of BCR, and time to BCR
were analyzed. BCR was defined as a post-RRP PSA level 
0.2 ng/mL [8]. BCR was stratified as early (occurring within
1 year of RRP) and late (occurring >1 year after RRP).
Suspected extraprostatic extension based on DRE was
defined as DRE positive (þ) and the absence of extrapro-
static extension in DRE was defined as DRE negative ().
Statistical analysis was performed using SPSS v.21 (IBM
SPSS Statistics version 21). The study variables were
investigated using visual and analytical methods
(KolmogoroveSimirnov test) to determine the normality of
their distribution. Normally distributed variables are shown
as mean  standard deviation. Dual comparisons between
groups were made using Student t test, ManneWhitney U
test, and Chi-square test. Multivariate logistic regression
analysis was used to identify the factors associated with
BCR. The level of statistical significance was set at
p < 0.05.Free/total PSA 13.97  7.78 14.88  6.92 0.51
Time to BCR  SD
(min)
19.65  12.8 17.36  14.37 0.52
BCR Z biochemical recurrence; GS Z Gleason score;
PSA Z Prostate-specific antigen; SD Z standard deviation;
SM Z surgical margin.Results
The study included 130 patients with locally advanced PCa
who underwent RRP. The mean age of the patients was
64.30  6.03 years, and the mean preoperative PSA levelwas 8.74  6.16 ng/mL. The final pathologic examination
showed that seven (5.4%) of the patients had T3a disease
and 123 (94.6%) had T3b disease. Additionally, perineural
invasion was observed in 67 (51.5%) patients.
In all, 93 (71.5%) of the patients had SM(þ), versus 37
(28.5%) who had SM(). There were no significant differ-
ences in mean age, preoperative PSA level, preoperative
prostate biopsy GS, prostate volume, or free/total PSA ratio
between SM(þ) and SM() patients, whereas the final pa-
thology GS was significantly lower in SM(þ) patients than in
SM() patients (p Z 0.001; Table 1). In total, four (57.1%)
of the seven patients with pT3a disease had SM(þ) and 89
(72.4%) of the 123 patients with pT3b disease had SM().
Among the 130 patients, 28 had BCR after RRP: 12 pa-
tients had early BCR, versus 16 with late BCR. BCR occurred
in 11.8% (11 of 93) of patients with SM(þ) and in 45.9% (17
of 37) of patients with SM(); the difference was significant
(p < 0.001). There was no significant difference in the
mean time to BCR after RRP between SM(þ) patients
(17.36  14.37 months) and SM() patients
(19.65  12.8 months). The mean follow-up period after
RRP in all patients was 32  17.08 months (range,
7e90 months), whereas the patients without BCR had a
mean follow-up of 30.6  17.4 months (range,
7e90 months).
Multivariate logistic regression showed that SM(þ) was
the only significant predictor of BCR after RRP (relative
risk, 0.163; 95% confidence interval (0.062e0.433);
p < 0.001) rather than DRE, lymph node involvement (LNI),
seminal vesicle involvement (SVI), or perineural invasion
(PNI). Moreover SM(þ) was associated with PNI (pZ 0.001),
but not with DRE, LNI, or SVI (Table 2).
Suspicion of extracapsular extension based on DRE was
noted in 34 (26.2%) patients. There were not significant
differences in mean age, PSA level, prostate volume, or the
free/total PSA ratio between the DRE(þ) and DRE() pa-
tients; however, there was a significant difference in pre-
operative prostate biopsy GS and final pathology GS
(p < 0.001 and p < 0.001, respectively). The time to BCR
after RRP was significantly longer in DRE() patients
(p Z 0.001). Furthermore, there was a positive correlation
between DRE(þ) and final pathology GS (p < 0.001); how-
ever, DRE(þ) was negatively correlated with SVI
(p < 0.001).
Table 2 Distribution of patients according to BCR status.
BCR() BCR(þ) Number of
patients
p
No. of patients
(n Z 130)
102 (78.5%) 28 (21.5%) 130
SM() 20 17 37 <0.001
SM(þ) 82 11 93
DRE() 79 17 96 0.07
DRE(þ) 23 11 34
SVI() 5 2 7 0.64
SVI(þ) 97 26 123
PNI() 56 11 67 0.14
PNI(þ) 57 12 69
LNI() 40 10 50 0.73
LNI(þ) 62 18 80
BCR Z biochemical recurrence; DRE Z digital rectal examina-
tion; LNI Z lymph node involvement; PNI Z perineural inva-
sion; SMZ surgical margin; SVIZ seminal vesicle involvement.
516 C. Ceylan et al.Discussion
Numerous tools for predicting the recurrence of PCa
following definitive treatment have been developed during
the past 20 years. The most well known of such tools are
the Kattan nomogram, the Stephenson nomogram, D’Amico
criteria, and CAPRA-S (Cancer of the Prostate Risk Assess-
ment score) [9e13]. Additionally, the Partin tables are used
to predict if PCa will be confined to the prostate, based on
GS, the PSA level, and the clinical stage of PCa [14]. In
addition to preoperative predictors, other factors associ-
ated with surgery and final pathology might play a role in
the recurrence of PCa; however, final pathology might not
be a reliable tool for predicting oncologic outcome, as some
patients with prostate-confined disease develop recurrence
and others with nonorgan confined PCa remain disease-free
[10,15].
SM(þ) is considered a significant predictor of disease
recurrence following RP [16e21]. In contrast, some re-
searchers report that there is no association between dis-
ease recurrence and the surgical margin status of RP
specimens [22]. Karakiewicz et al. [19] observed a 3.7-fold
increase in the risk of progression after RP in patients with a
final pathology of SM(þ) (p Z 0.001), and reported that
surgical margin status was associated with final pathology
GS (p Z 0.008) and LNI (p < 0.001). It was also reported
that the frequency of SM(þ) in patients with pT3a disease
(30.5%) and pT3b-4 disease (48.5%) was significantly higher
than in those with pT2 disease (8.2%) (p < 0.001) [18]. The
same study also reported that the BCR rate in patients with
SM(þ) was 64.3% and that the local recurrence rate was
18.6%, both of which were significantly higher than in pa-
tients with SM() (p < 0.001) [18].
Boorjian et al. [20] suggested that SM(þ) is a risk factor
for BCR, local recurrence, and the need for salvage ther-
apy. The 10-year BCR-free rate in patients with SM(þ) was
56%, versus 77% in those with SM(); the difference was
significant (p < 0.001). Among the 3651 patients in their
study with SM(þ), 56.8% had pT2N0 disease, 21.7% had
T3aN0 disease, and 13.4% had T3b/4N0 disease. Alkhateebet al. [21] studied the effect of SM(þ) on BCR after RP,
according to PCa risk groups. The SM(þ) rate in patients
with pT2 disease (13.6%) was significantly lower than in
those with pT3 disease (35.7%) (p < 0.0001). At a median
follow-up of 79 months, the biochemical progression-free
survival (BPFS) rate in patients with SM(þ) was 79.9%,
compared with 93.8% in those with SM() (p < 0.001). The
researchers concluded that SM(þ) might be a predictor of
BPFS in patients with moderate- and high-risk PCa, but not
in patients with low-risk disease. Another study reported
that SM(þ) was associated with BCR in patients with pT3a
disease and a GS 6, but not in patients who had organ-
confined high-grade PCa, and SVI and LNI [23].
In contrast with these earlier studies, Stamey et al. [22]
reported that SM(þ) is not an independent predictor of BCR
after RP. In another study, a preoperative PSA level >10 ng/
mL and a final pathology GS 7 were associated with BCR in
patients with pathologically organ-confined disease and
SM() [15]. Additionally, the BCR risk in patients with
organ-confined PCa (pT2) and SM(þ) was found similar in
those with pT3 disease and a PSA level 10 ng/mL by
Eminaga et al. [6]. Moreover, the SM(þ) rate in patients
with pT2, pT3a, and pT3b PCa was 24.7%, 54.9%, and 58.2%,
respectively. Furthermore, the preoperative PSA level in
patients with SM(þ) was significantly higher (13.1 ng/mL)
than in those with SM() (9.4 ng/mL) (p < 0.001). SM(þ)
was also associated with higher rate of BCR in pT2 patients
than was SM(), but not in pT3 patients [6]. In concordance
with Eminaga et al. [6], Corcoran et al. [24] reported that
SM(þ) is a risk factor for BCR in patients with intermediate
disease (PSA, 10e20 ng/mL; stage, pT2; GS, 7). They also
noted that the BCR risk in high- and low-risk patients is
associated with intrinsic tumor biology, and that SM(þ) has
a limited effect on BCR [24].
In the present study, BCR occurred in 11.8% of patients
with SM(þ) and in 45.9% of patients with SM(). Multivar-
iate regression analysis in the present study showed that
SM(þ) was the only significant negative predictor of BCR.
Accordingly, the findings show that SM(þ) is not always
indicative of BCR after RP in patients with locally advanced
PCa. This finding is in contrast to the generally accepted
understanding of the effect of SM(þ) on BCR, and the dif-
ference might be associated with the present study’s small
patient population and the short duration of follow-up. In
addition, as mentioned above, intrinsic tumor biology might
have the greatest effect on BCR in patients with locally
advanced PCa following RP.Limitations
In the present study SM(þ) in patients with T3a and T3b
disease was 57.1% and 72.4%, respectively. Although the
SM(þ) rate in the present study’s patients with T3a disease
was similar to that in earlier reports, the SM(þ) rate in the
present study’s patients with T3b disease was higher than
previously reported. This difference might have been due
to the long learning curve of different surgeons or due to
stiffness and extent of the cancer tissue. Moreover, not all
surgeons in the present study had undergone uro-oncology
fellowship training. As such, we think additional larger-
scale prospective studies based on surgery performed by
Recurrence in locally advanced prostate cancer 517only one surgeon or only those with uro-oncology training
are needed.
Conclusion
SM(þ) is widely considered a poor prognostic factor and a
predictor of BCR in PCa patients after RP. Despite the large
number of relevant studies, the effect of SM(þ) on PCa
progression and cancer-specific survival following RP re-
mains unclear. Furthermore, the accuracy of preoperative
prediction of SM(þ) in RP specimens via radiological imag-
ing, physical examination, and the preoperative PSA level
and GS has yet to be proven.
The present findings show that surgical SM(þ) in RP
specimens is not always indicative of BCR in patients with
locally advanced PCa. RP should be considered an effective
treatment choice for selected patients with locally
advanced PCa, despite the high SM(þ) rate. Additional
larger-scale prospective randomized studies are needed to
confirm the present study’s findings.
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